Company Events
- Categories:About Us
- Time of issue:2021-05-28 15:33:40
- Views:0
Description:
Information
On June 22, 2020, the company produced 200 tons of atorvastatin key intermediate L1, 100 tons of atorvastatin calcium, 50 tons of clopidogrel bisulfate and other three API projects passed the environmental protection "three simultaneous" completion acceptance.
On June 3, 2020, Zhejiang Lepu Pharmaceutical was evaluated by the two-level human and social security departments of the city and was selected as the second batch of pilot enterprises for vocational skill level recognition in the city.
On March 31 and April 14, 2020, the 1201 workshop and 1007 workshop incubator technical renovation project passed the safety condition review organized by the Jiaojiang District Emergency Management Bureau.
On March 13, 2020, the company won the "2019 Meritorious Enterprise Award" and "Science and Technology Innovation Enterprise Award" in Jiaojiang District, and ranked 5th in the district for tax payment in 2019.
On March 11, 2020, the company won the 24th place in the taxation of private enterprises in Taizhou in 2019.
On March 11, 2020, the company passed the certification of the integration of industrialization and industrialization management system and obtained the certification.
On February 28, 2020, the company donated 12,000 masks (worth 27,650 yuan) to the Red Cross Society of Jiaojiang District.
On February 02, 2020, President Hong, on behalf of Zhejiang Lepu Pharmaceutical, donated 500,000 yuan to the People's Government of Jiaojiang District to support the prevention and control of the novel coronavirus pneumonia epidemic.
On the morning of February 22, 2020, the launch ceremony of key industrial projects in Jiaojiang District and the launch ceremony of our company's 3 billion solid preparation technical transformation project were held in our company.
On February 17, 2020, the company fully resumed work.
On February 11, 2020, after the new coronavirus pneumonia epidemic was effectively controlled, the company's preparation workshop became the first medical and chemical company in Jiaojiang District to resume work.
On November 6, 2019, the company's "Chemical Enzymatic Combination Catalytic Synthesis of Rosuvastatin Calcium" project was listed as a key high-tech product development project in Zhejiang Province in 2019.
On October 31, 2019, the company's technology center was jointly identified as Zhejiang Province's 2019 Provincial Enterprise Technology Center by the Provincial Department of Economy and Information Technology, the Provincial Department of Finance, the Provincial Taxation Bureau, and Hangzhou Customs.
On July 12, 2019, the company was listed as a post-doctoral innovation practice base
On April 22, 2019, the sixth meeting of the sixth board of directors of the company was held in the conference room on the third floor of the company.
On February 12, 2019, the 2019 District Cadre Conference was held in Jiaojiang Theater. Our company won the honorary title of the 6th place in the 2018 annual tax payment enterprise.
On February 26, 2019, it successfully passed the US FDA inspection again and obtained the certificate.
On February 11, 2019, our company won the top 50 taxpayers of Taizhou private enterprises in 2018 (No. 37)
On January 16-17, 2019, the GMP inspection team conducted a GMP on-site inspection of our company’s export of raw materials (atorvastatin calcium, rosuvastatin) to the EU, and found that it basically complied with the "Good Manufacturing Practice for Drugs (Revised in 2010)" "Requirements. And obtained the export of EU raw materials (rosuvastatin calcium, atorvastatin calcium) certification documents.
On January 14-16, 2019, the GMP certification inspection team conducted a GMP certification on-site inspection of our APIs (atorvastatin calcium, norfloxacin), and the inspection team found that they were in compliance with the "Good Manufacturing Practice for Drugs" (2010 version) ) Requirements.
On December 21, 2018, the technical transformation project of our company's incubator workshop passed the environmental assessment.
On December 3-7, 2018, FDA inspectors conducted on-site inspections of atorvastatin and other APIs and intermediates.
On November 5, 2018, at the 2018 Taizhou International Talent Cooperation Conference. As the only national model academician workstation in Taizhou, our company attended the licensing ceremony.
On October 21, 2018, after nearly half a year of intense and orderly construction, the company's comprehensive building successfully completed its roof.
On October 8, 2018, our company learned from Taiwan Huanzhen (Jiao) [2018] No. 8 document that Lepu Technology's 3 billion solid preparation technical transformation project (Phase 1) all passed the environmental protection acceptance.
On September 26, 2018, the Jiaojiang District Planning Bureau organized the company’s annual output of 200 tons of atorvastatin intermediate L1, 50 tons of rosuvastatin intermediate R1.5, 30 tons of M-C, 100 tons of 4MA, and 60 tons. The ton 3 oxo technical transformation project (supporting storage room technical transformation project) has been checked and accepted and passed.
On August 29, 2018, our company obtained a pollutant discharge permit after the name change.
On August 9, 2018, our company obtained the newly renamed drug production license.
On August 2, 2018, the Zhejiang Provincial Department of Commerce awarded our company Kanglide as the Zhejiang Famous Export Brand.
In 2018, the company's "Kanglide" trademark was awarded Zhejiang Famous Export Brand.
From July 30 to August 2, 2018, the GMP inspection team of Zhejiang Food and Drug Administration came to the company for a three-and-a-half-day GMP audit, and verified that the company's production activities were in compliance with GMP production standards.
On July 24, 2018, with the approval of Zhejiang Administration for Industry and Commerce, "Zhejiang Xindonggang Pharmaceutical Co., Ltd." was renamed "Zhejiang Lepu Pharmaceutical Co., Ltd.".
On July 17, 2018, we received the "Approval for Supplemental Drug Application" for "Atorvastatin Calcium Tablets" reviewed and issued by the National Medical Products Administration. Both the 10mg and 20mg specifications of the product passed the generic drug quality and efficacy consistency evaluation .
From May 31 to June 2, 2018, two EDQM prosecutors came to the company to conduct a three-day GMP audit. After inspection, the company's production activities are in compliance with GMP production specifications and CEP requirements.
From April 17 to 21, 2018, the inspector of the Office of Consistency Evaluation of the State Food and Drug Administration conducted a five-day on-site inspection of the company's atorvastatin calcium tablets (10mg, 20mg), and the inspection site basically met the requirements. .
On March 6, 2018, the groundbreaking construction of the company's complex building integrating quality inspection, R&D and office.
On March 12, 2018, the company's major shareholder-Lepu (Beijing) Medical Equipment Co., Ltd., through the electronic network of Zhejiang Property Exchange, bid for the new Donggang Pharmaceutical held by Zhejiang Materials and Chemicals Group Co., Ltd. at a price of 1.05 billion yuan 45% equity. After this transaction, Lepu (Beijing) Medical Devices Co., Ltd. holds 98.95% of Xindonggang Pharmaceutical.
On February 12, 2018, the company's newly built 301 preparation workshop passed GMP certification.
In December 2017, the company was awarded the title of Zhejiang AAA-level Contract-abiding Enterprise.
On December 8, 2017, the civil construction of the solid preparation workshop with an annual output of 3 billion tablets passed the completion acceptance.
On December 8, 2017, Zhejiang Xindonggang Pharmaceutical Co., Ltd. Academician Expert Workstation was recognized by the China Association for Science and Technology as the "Demonstration Academician Expert Workstation", becoming the first national-level demonstration academician expert workstation in Taizhou.
On September 20, 2017, Xindonggang Pharmaceutical was awarded the honorary title of “The First Batch of Demonstration Units in Zhejiang National Science and Technology Achievement Transfer and Transformation Demonstration Zone”.
On June 22, 2017, Zhejiang Province's major science and technology project-"Chemical-Enzymatic Combined Catalytic Synthesis of Atorvastatin Technology Development and Industrialization Project" passed the acceptance of Zhejiang Science and Technology Department.
The construction of the new storage area started on June 8, 2017.
On March 21, 2016, the ground-breaking construction of a solid preparation workshop with an annual output of 3 billion tablets.
In December 2015, the "Atorvastatin Calcium Chemistry-Enzymatic Synthesis Key Technology and Industrialization" project won the "Zhejiang Science and Technology Progress First Prize";
In December 2015, the "High-purity Norfloxacin and Moxifloxacin Green Synthesis Technology Development and Industrialization" project won the "Zhejiang Province Science and Technology Progress Second Prize";
In December 2015, the "Atorvastatin Calcium Tablets and Its API Industrialization" project won the National Torch Program Industrialization Demonstration Project Certificate;
In April 2015, the company successfully passed the re-identification of high-tech enterprises.
In February 2015, the Provincial Certification Center carried out GMP on-site inspection certification for atorvastatin calcium products, and was successfully passed. On January 24, 2015, Zhejiang Xindonggang Pharmaceutical Co., Ltd. held the first board of directors of the sixth session and elected a new board of directors. Wei Zhanjiang served as chairman and Hong Huabin as general manager.
On January 22, 2015, Zhejiang Xindonggang Pharmaceutical Co., Ltd. was named "Provincial Innovative Pilot Enterprise";
On January 20, 2015, Zhejiang Xindonggang Pharmaceutical and Biochemical Research Institute was established.
In December 2014, Lepu (Beijing) Medical Equipment Co., Ltd. acquired 51% of the company's shares and became the company's largest shareholder.
In September 2014, the company was included in the top 500 (282) of the main business income of China's pharmaceutical industry in 2013, and the top 500 (335) of the total profit of China's pharmaceutical industry.
On August 25-29, 2014, the company's products such as atorvastatin calcium, rosuvastatin calcium and other APIs and intermediates were subject to the CGMP on-site inspection by the U.S. inspector, and again passed the FDA re-certification with "0483".
On August 30, 2014, the "Atorvastatin Calcium Chemistry-Enzymatic Synthesis Key Technology and Industrialization" project passed the scientific and technological achievement appraisal meeting in Hangzhou.
On March 6, 2014, the company established the first Xindonggang order class in the School of Biology and Chemical Engineering, Taizhou Vocational and Technical College.
In February 2014, the company's preparations (tablets, capsules) passed the new version of GMP certification for medicines.
On December 4, 2013, the company developed "a method for preparing linezolid crystal form I by the suspension crystallization method" and obtained the national invention patent certificate.
In April 2013, Atorvastatin calcium tablets received approval for drug registration.
In February 2013, Norfloxacin passed the on-site CGMP inspection of Jazmp, Slovenia.
In December 2012, Norfloxacin passed the Korean KFDA's on-site GMP inspection.
In October 2012, the State-owned Assets Supervision and Administration Commission of the People's Government of Zhejiang Province issued Zhejiang State-owned Enterprise Reform No. 22 "Approval on the Reorganization Plan of Zhejiang Hongyuan Pharmaceutical Co., Ltd. and Zhejiang Xindonggang Pharmaceutical Co., Ltd.", and agreed to the reorganization plan. A strong alliance with Zhejiang Materials Industry Group was realized, and Zhejiang Materials Industry Chemical Group Co., Ltd. became the major shareholder of the company.
In September 2012, the company was recognized as the "Zhejiang Academician Expert Workstation" by the Talent Work Leading Group of the Zhejiang Provincial Committee of the Communist Party of China.
In August 2012, tablets and capsules passed the extended on-site inspection of the drug GMP certificate.
In August 2011, the carbapenem antibiotic meropenem was selected as a project of the National Torch Program.
In May 2011, the company was identified as the first batch of "Taizhou Academician Expert Workstations" by Taizhou City
In April 2011, atorvastatin sodium, atorvastatin intermediate L-1, rosuvastatin intermediate R-1.5 and rosuvastatin intermediate RJS-3 passed the US FDA on-site CGMP inspection (re-certification) .
The first trade union committee was established in March 2011.
In December 2010, the synthesis process of norfloxacin won the national invention patent certificate.
In November 2010, a method for preparing amorphous statin calcium with crystalline atorvastatin sodium was awarded the national invention patent certificate.
In October 2010, the raw materials sertraline hydrochloride, bromhexine hydrochloride, and fexofenadine hydrochloride passed the pharmaceutical GMP certification organized by Zhejiang Pharmaceutical Certification Center.
In March 2010, the raw materials doxazosin mesylate and atorvastatin calcium passed the drug GMP certification organized by Zhejiang Pharmaceutical Certification Center.
In February 2010, the raw materials fexofenadine hydrochloride and fexofenadine hydrochloride capsules were approved for drug registration.
In January 2010, the raw material drug atorvastatin calcium was approved for drug registration.
In 2010, the company was awarded the advanced collective of Zhejiang Association for Science and Technology Lecture Competition.
In 2010, rovastatin won the third prize of Zhejiang Excellent Industrial New Product and New Technology.
In 2010, the green chemical project of Sertraline Hydrochloride was included in the Provincial Major Science and Technology Project.
In 2010, the company was selected as Zhejiang Patent Demonstration Enterprise.
In January 2010, the "Kangdeli" trademark was appraised as Zhejiang Famous Trademark by Zhejiang Administration for Industry and Commerce.
In November 2009, the new workshop of the raw material drug norfloxacin passed the drug GMP certification organized by Zhejiang Pharmaceutical Certification Center
In July 2009, Atorvastatin sodium passed the on-site CGMP inspection by the British MHRA.
In 2009, the key intermediate of rosuvastatin calcium, a new lipid-lowering drug, was included in the provincial key industrialization project.
In 2009, the research and development of fexofenadine hydrochloride won the second prize of Zhejiang Chemical Industry Science and Technology Award.
In 2009, the research on new technology of rovastatin production won the third prize of Science and Technology Progress of the National Federation of Industry and Commerce.
In June 2009, the preparation method of high-purity crystalline sodium atorvastatin obtained the invention patent certificate.
In June 2009, a non-equal ratio cis-sertraline hydrochloride mixture obtained the invention patent certificate.
In May 2009, the preparation method of high-purity atorvastatin calcium obtained the invention patent certificate.
In January 2009, the preparation method of 4-[4-(1-ethoxyacyl-1-methylethylbenzene)]-4-oxobutyric acid obtained the invention patent certificate.
In September 2008, the company was jointly named the first batch of high-tech enterprises (new version) by Zhejiang Provincial Department of Science and Zhejiang Provincial Department of Finance.
In July 2008, the research on new technology of rovastatin production won the first prize of Zhejiang Chemical Industry Science, Technology and Technology Award.
In May 2008, the company was awarded the provincial safety standardization certificate of hazardous chemical industry and the medal of the provincial safety standardization enterprise.
In January 2008, atorvastatin sodium passed the on-site CGMP inspection of the US FDA.
In December 2007, rovastatin was listed as a high-tech product in Zhejiang Province.
In September 2007, tablets, capsules, granules and the raw material drug norfloxacin passed the drug GMP re-certification organized by Zhejiang Pharmaceutical Certification Center.
In April 2007, the company was rated as one of the top ten enterprises in Zhejiang Province's pharmaceutical industry in 2006 by Zhejiang Pharmaceutical Industry Association. In April 2006, the raw material nevirapine passed the pharmaceutical GMP certification organized by Zhejiang Pharmaceutical Certification Center.
In 2006, the company was awarded the 2004 AAA tax credit rating by Zhejiang State Taxation Bureau and Zhejiang Local Taxation Bureau.
In 2006, the industrialization of key intermediates of the new lipid-lowering drug rosuvastatin was listed as a national innovation fund project.
In November 2005, both the raw material drug nevirapine and dispersible tablets were approved for drug registration. At the same time, they obtained the new drug certificate of the fourth class of the raw material drug and the new drug certificate of the fifth class of the dispersible tablet chemical.
In November 2005, Sertraline Hydrochloride Tablets obtained drug registration approval and at the same time obtained the new drug certificate of the fourth category of chemical drugs of this variety.
In October 2005, the raw materials of bromhexine hydrochloride and sertraline hydrochloride passed the pharmaceutical GMP certification organized by Zhejiang Pharmaceutical Certification Center.
In September 2005, the bulk drug Sertraline Hydrochloride was approved for drug registration.
In 2005, fexofenadine hydrochloride was listed as a technological innovation project plan of Zhejiang Province.
In 2005, the pilot trial and clinical research of nevirapine was listed as a provincial science and technology plan project.
In May 2005, 4-cyano-3R(one)-hydroxy-butyric acid ethyl ester passed the acceptance of the innovation fund project.
In May 2005, the company was rated as a key high-tech enterprise of the National Torch Plan.
April 2005
The raw material doxazosin mesylate has passed the GMP certification organized by Zhejiang Pharmaceutical Certification Center.
In April 2005, the bulk drug bromhexine hydrochloride was approved for drug registration.
In January 2005, the bulk drug and tablets of doxazosin mesylate were approved for drug registration.
2004 The key intermediate of atorvastatin L1 won the third prize of Zhejiang Science and Technology Award.
In 2004, Tegaserod maleate was listed as a technological innovation project plan of Zhejiang Province.
In 2004, the pilot test of tegaserod maleate and the clinical study of tablets were listed as a provincial science and technology plan project.
In June 2004, the raw materials and tablets of doxazosin mesylate were awarded the second class new drug certificate.
In May 2004, the key intermediate of atorvastatin with an annual output of 2 tons was listed as the national torch plan project certificate.
In 2003, the company was rated as a provincial-level high-tech enterprise in Zhejiang Province.
In 2003, the company was rated as a provincial-level high-tech research and development center.
In 2003, the synthesis process of a new generation of anti-hyperlipidemia API (Rovastatin) was listed as a provincial science and technology plan project.
In 2003, methyl 3-oxopentanoate was recommended as a national excellent scientific and technological product.
In December 2003, it absorbed and merged Zhejiang Donggang Pharmaceutical Co., Ltd., and approved by the Zhejiang Provincial Drug Administration, agreed to change its name to "Zhejiang Xindonggang Pharmaceutical Co., Ltd.".
In May 2003, the raw material norfloxacin passed the drug GMP certification organized by Zhejiang Provincial Drug Administration, becoming the first drug GMP certification pilot unit after the National Bureau delegated the GMP certification authority to the provincial bureau.
In April 2003, 4-cyano-3R(one)-hydroxybutyrate was included in the national torch plan project.
In April 2003, 4-cyano-3R(one)-hydroxybutyrate was rated as a provincial high-tech product.
In April 2003, 4-cyano-3R(one)-hydroxybutyrate ethyl ester won the Provincial Science and Technology Progress Award.
In October 2002, the solid preparation workshop passed the drug GMP certification organized by the State Drug Administration, and obtained GMP certificates for tablets, capsules, and granules.
In August 2002, Norfloxacin was listed as the second batch of high-tech products in Zhejiang Province in 2002.
In 2002, ethyl 4-cyano-3R(one)-hydroxybutyrate was awarded the National Innovation Fund.
In 2002, doxazosin mesylate was listed as a provincial science and technology plan project.
In 2002, the company passed the ISO9001, ISO14001 management system certification.
In September 2001, the company obtained the "Drug Production License".
In January 2001, Zhejiang Xindonggang Pharmaceutical Chemical Co., Ltd. was established.
Search for
LINKS：
Copyright © 2021 Zhejiang LePu Pharmaceutical Co., Ltd. All rights reserved 浙ICP备17026965号 Powered by www.300.cn